The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Napabucasin Add-On Shows Efficacy in Colorectal Cancer: Sumitomo Dainippon
January 24, 2017
- Takecab Most Heavily Pitched Drug in HP Market in November: Anterio
January 24, 2017
- Kansai Medico Issues Apology over Harvoni Counterfeits
January 24, 2017
- Ferring Speeding Up R&D in Core Sectors, Positive on Licensing and M&A: Japan CEO
January 23, 2017
- Stivarga Gets Priority Review for 2nd-Line Liver Cancer Treatment
January 23, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Towa
January 23, 2017
- BMS-Ono Pair, Merck Settle Keytruda Patent Suits
January 23, 2017
- Opdivo Extends OS in Advanced Gastric Cancer: Ono
January 23, 2017
- Takeda Taps NY Biotech to Develop Its Pediatric Epilepsy Med
January 20, 2017
- Daiichi Sankyo’s 2nd ADC Now in Japan PI/II for HER3-Positive Breast Cancer
January 20, 2017
- Hiroshi Kasamoto Named as Bioverativ Japan President
January 20, 2017
- JCR to Initiate PI/II Study in March of Therapeutic Enzyme for Hunter Syndrome that Applies Blood-Brain Barrier Technology
January 20, 2017
- Ethical Drug Sales Down 3.6% in November: Crecon Report
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Nichi-Iko, Meiji Seika Pharma Obtain New Indications for Zosyn Generics
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
- Mitsubishi Tanabe to Shake Up Organization in April
January 17, 2017
- Eisai to Take Over Rights to Roche/Chugai’s Insomnia Drug
January 17, 2017
- FDA Orphan Status Granted to Nippon Shinyaku’s DMD Med
January 17, 2017
- Dasotraline Meets Primary Endpoint in PII/III Study in Adult Patients with Binge Eating Disorder: Sumitomo Dainippon
January 17, 2017
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…